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1.0 EXECUTIVE SUMMARY 
 
The strategy takes into account the proposed changes in work load based on trend analysis 
of previous years. The strategy also takes into account the problem of drugs and driving and 
the need for the Medical Bureau of Road Safety to accommodate both the number of 
specimens for analysis and also in the type of drugs to be analysed.  
 
 
1.1 MISSION 
 
The Mission of the Medical Bureau of Road Safety (Bureau) is to provide a high quality 
National forensic service in alcohol/drug (intoxicant) detection in support of the effective 
operation of the road traffic legislation. 
 
 
1.2 5 YEAR OBJECTIVES 
 
1. To continue to provide a high quality national forensic service in alcohol and drug 
analysis, the provision of Bureau certificates and Court assistance. 
 
2. To maintain the ISO17025 accredited status achieved for the analytical 
programmes within the Bureau and to extend the scope of accreditation to 
additional areas. 
 
3. To adapt and incorporate into the Bureau activities any legislative requirements 
over the five year period. 
 
4. To build up a forensic toxicology (including alcohol) knowledge base within the 
Bureau scientific staff. 
 
5. To increase Garda capacity to detect intoxicated drivers by continuing to provide 
drug testing and alcohol devices.  
 
6. To ensure that all work in the Bureau is maintained and improved where possible 
to a high standard of quality that is required of a national forensic laboratory in a 
cost effective and efficient way. 
 
7. To assist with education, enforcement and legislation measures that are set out in 
the National Road Safety Strategy 2013 – 2020 and beyond. 
 
8. To maintain effective financial management systems and operate within best 
accounting practices and frameworks. 
 
9. To ensure that the Bureau has Corporate Governance in operation and has the 
ability to objectively and effectively assess management and corporate 
performance. 
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1.3 KEYS TO SUCCESS 
 
In order for the Bureau to achieve its objectives it relies on good planning, provision of 
adequate resources, staff and instrumentation for the detection of alcohol and/or drugs. 
 
 
Planning 
 
The Bureau is a service organisation and in order to provide an efficient service it must 
know the requirements of its clients. The Bureau communicates regularly with the 
Department of Transport, Tourism and Sport (DTTAS) and the Garda National Roads 
Policing Bureau (GNRPB) in relation to the service being provided and the legislative and 
operational changes that are required to continue to provide a reliable and efficient service 
in support of the road traffic legislation.  
 
Careful planning for the most efficient use of resources of the Bureau is constantly required. 
 
The Chief Analyst and Principal Analyst are involved in the Preliminary Drug Testing Review 
group along with members from DTTAS and GNRPB.  
 
The Bureau is made aware of policing plans and takes particular notice of increases in Roads 
Policing personnel as this leads to increased enforcement which increases specimens being 
forwarded to the Bureau. The Current Policing (2018) plan includes year on year increase in 
staff. 
 
In order for timely planning the Bureau must be aware of any legislative change that will 
affect the workload. 
 
Resources 
 
The Bureau depends on the grant given by the DTTAS and tries to plan and work within that 
budget. However it is the work of An Garda Síochána that dictate the volume and nature of 
the work that is carried out by the Bureau, i.e. the number of specimens forwarded and 
whether it is alcohol and/or drug analysis that is required.  To maintain supplies of specimen 
collection kits to An Garda Síochána, roadside breath alcohol devices, evidential breath test 
instruments and PDT devices requires adequate resources. The Bureau must deliver both 
quality and value for money and will continue to review its activities to ensure it operates in 
a cost effective manner. 
 
Staffing 
 
The analytical work and associated activities requires highly trained and competent staff. 
Sufficient staff to carry out the functions of the Bureau is essential. The law requires that 
analysis and issuing of results are carried out as soon as practicable. All scientific staff 
require suitable and continuous training to maintain their competence and be suitable expert 
witnesses. The reputation of the Bureau has been built up over forty nine years of good 
scientific and administrative practice and each staff member works hard to maintain the high 
standard required of a national forensic laboratory. The increase in workload in 2018 have 
placed increased demands which can only be met by the allocation of additional staff 
requested in 2018. 
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Instrumentation 
 
The Bureau cannot operate without instrumentation and continues to provide the laboratory 
with suitable analytical instruments keeping abreast of innovation in technology both in the 
field of alcohol and drug detection. The Bureau also issues the Gardaí with evidential breath 
testing instruments and preliminary drug testing devices in selected Garda stations. Devices 
for roadside preliminary breath alcohol and preliminary drug testing are also issued. The 
Bureau will continue to investigate the developments in both chemical drug testing and 
alcohol testing devices. The Bureau requires that its testing equipment is calibrated and in 
good working order.  
 
 
Information Technology 
 
The Bureau has increased its information technology resources in line with increased 
demands in all aspects of the work of the Bureau. The Bureau operates a local Area Network 
to maintain the security and integrity of all work. A fibre optic cable back up system is in 
place and a high level of back up procedures and monitoring are in place. The Bureau 
maintains a computerised document control system and a laboratory information system 
(LIMS) The Bureau will continue to keep abreast of changes in IT technology and IT 
security.  
 
 
2.0 MANAGEMENT SUMMARY 
 
The Board of the Bureau comprises of five members (including the Director) which is 
appointed by the Minister of Transport, Tourism and Sport for a five year term. The current 
Board members are Dr. Declan Bedford (Chairman), Professor Denis Cusack (Director), 
Professor Patricia Fitzpatrick. and Mr. Michael McDermott. 
 
The Director is responsible for managing the day to day business of the Bureau. 
The Bureau has made an arrangement with UCD for the use by the Bureau of its staff, 
premises and equipment for the majority of its functions.  
 
The Bureau had made an arrangement with the Eurofins for the use by the Bureau of its 
staff, premises and equipment for selected confirmatory analysis for drugs. From May 2018 
all testing is carried in the Bureaus UCD facility and it is not planned that any other 
laboratory will be used for testing in the lifetime of this strategy. 
 
The functions of the Bureau are divided into different programmes and services: Alcohol 
which includes Blood & Urine Alcohol and Breath Alcohol; Toxicology; Quality Assurance; 
Information Technology and Corporate Services. 
 
All areas have been developed and the IT and toxicology programmes in particular have 
expanded in recent years in line with increase in demands in all aspects of the work of the 
Bureau.  
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2.1 ORGANISATIONAL STRUCURE 
   
A diagrammatic presentation of the organisational structure of the Bureau is outlined on the 
next page.  
 
 
2.2 EXECUTIVE MANAGEMENT TEAM 
 
Director: Professor Denis Cusack  
Head of Laboratories (Chief Analyst): H. Kearns 
Principal Analyst Alcohol Programme:  L. Lawlor 
Principal Analyst - Quality Manager: S. McDonald 
Principal Analyst Toxicology Programme: Dr R. Maguire 
Head of Administration (Senior Administrator): T. Clarke  
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3.0     ESTABLISHMENT OF THE MEDICAL BUREAU OF ROAD SAFETY 
 
The Medical Bureau of Road Safety (Bureau) is responsible for the chemical testing of 
intoxicants in driving in Ireland. It is a corporate body established in November 1968 by 
the Minister for Local Government under Part V of the Road Traffic Act 1968.The 
Ministers title was altered to Minister for the Environment & Local Government on 22nd 
July 1997.  In June 2002 the Medical Bureau of Road Safety came under the aegis of the 
Minister for Transport, Tourism and Sport following the transfer of departmental 
Administration and Ministerial Functions Order 2002.   Since 2011 the Medical Bureau of 
Road Safety is currently under the Department of Transport, Tourism and Sport 
 
 
 
3.1  FUNCTIONS OF THE MEDICAL BUREAU OF ROAD SAFETY 
 
The Functions of the Bureau are laid down in the Road Traffic Acts 1968 – 2016 
 
 Receipt and analysis of specimens of blood and urine forwarded to the Bureau 
and the issue of reports on such analysis—for the concentration of alcohol. 
 Receipt and analysis of specimens of blood and urine forwarded to the Bureau 
and the issue of reports on such analysis—for the presence of a drug or drugs. 
 Receipt and analysis of specimens of blood and urine forwarded to the Bureau 
and the issue of reports on such analysis—for the concentration of a drug or 
drugs. 
 Provision of equipment for the taking of such specimens. 
 Approval, supply and testing of apparatus for indicating the presence of alcohol in 
the breath. 
 Approval, supply and testing of apparatus for indicating the presence of drugs in 
oral fluid. 
 Approval, supply and testing of apparatus for indicating the concentration of 
alcohol in the breath. 
 Provide assistance to the Court.  
 Research on drinking and drugs in relation to driving, including the methods of 
determining the amount of alcohol or drugs in a person’s body and the 
epidemiology of driving under the influence of intoxicants. 
 
4.0  GOAL 
 
It is the continuing policy of the Medical Bureau of Road Safety to achieve and maintain a 
high standard of quality in all aspects of the work of the Bureau. 
 
 
4.1      OBJECTIVES 
 
The programme of work for the Medical Bureau of Road Safety will continue to focus on 
the main legal responsibilities as set out in the Road Traffic Acts and the action plan of 
the National Road Safety Strategy 2013-2020 and beyond.  
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4.2   SHORT- TERM GOALS (1 -2 YEARS) 
 
Blood & Urine Alcohol Programme 
 
1. To maintain ISO 17025 accredited status for blood and urine alcohol analysis 
carried out in the Bureau. (Point 2 of the 5 year objectives) 
 
2. To maintain the provision of equipment to Gardaí for the taking of specimens. 
(Point 1 of 5 year objectives) 
 
3. To review the equipment (kits) provided to the Gardaí for the provision of blood 
and urine specimens 
 
4. To review reporting of analysis format.  (Point 4 of 5 year objectives) 
 
 
Breath Alcohol Programme 
 
1. To maintain ISO 17025 accredited status for performance testing of evidential 
breath alcohol testing instruments installed in Garda stations by Bureau scientists. 
(Point 2 of 5 year objectives) 
 
2. To continue to support the Gardaí in the operation of the EBT instruments in 
Garda stations. (Point 1 of 5 year objectives) 
 
3. To maintain ISO 17025 accredited status for performance testing of roadside 
breath alcohol testing devices by Bureau scientists. (Point 2 of 5 year objectives) 
 
4. To continue to support the mandatory alcohol testing legislation and to 
replacement roadside breath alcohol testing devices with Dräger 7510 devices. 
(Point 1 of 5 year objectives) 
 
5. To support the training of Garda operators in the use of Evidential Breath Testing 
instruments. (Point 6 of 5 year objectives) 
 
6. To maintain the Laboratory Information Management system for PDT devices and 
to develop an in-house IT Solutions for EBT management and scheduling.  (Point 
1 of 5 year objectives) 
 
7. To access the need to tender for replacement of Evidential Breath Testing 
instruments type. 
 
 
Toxicology Programme 
 
1. To maintain ISO 17025 accredited status for preliminary and confirmatory blood 
and urine drug analysis carried out in the Bureau. (Point 2 of 5 year objectives) 
 
2. To support the training of Garda instructors in Road Traffic Impairment Testing 
(RTIT) (Point 6 of 5 year objectives) 
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3. To support the training of Garda instructors in Preliminary Drug Testing Device 
and/or tester use (PDT) (Point 6 of 5 year objectives) 
 
4. To continue to build up knowledge of PDT and drug testing generally. (Point 6 of 
5 year objectives) 
 
5. To continue to supply and test PDT devices to AGS, a PDT programme. (Point 6 of 
5 year objectives) 
 
6. To review the use of PDT devices. 
 
7. To expand the drug screening panel within the Bureau at UCD premises. (Point 5 
of 5 year objectives) 
 
8. To expand the drug confirmatory programme within the Bureau at UCD premises. 
(Point 5 of 5 year objectives) 
 
9. To implement a new reporting scheme to provide greater detail on Certificates of 
Analysis. 
 
 
All programmes 
 
1. To continue to provide court assistance. (Point 1 of 5 year objectives) 
 
2. To review reporting of analysis format.  (Point 4 of 5 year objectives) 
 
3. To ensure that the Bureau facilitates the Official Languages Act.  (Point 3  of 5 
year objectives) 
 
4. All work in the Bureau will be maintained and improved where possible to a high 
standard of quality that is required of a national forensic laboratory. (Point 7 of 5 
year objectives) 
 
5. To improve and develop the recording, storage and retrieval of data in the 
Bureau. (Point 7 of 5 year objectives) 
 
6. To assist with education, enforcement and legislation measures as outlined in the 
National Road Safety Strategy 2013 to 2020 and beyond. (Point 8 of 5 year 
objectives) 
 
 
Corporate Services 
 
1. To ensure that the Bureau has its structures and processes in place to 
conform to the Code of Practice for the Governance of State Bodies.  
      (Point 10 of 5 year objectives) 
 
2. To improve and develop the management of the accounting records and  
      data in the Bureau.  (Point 9 of 5 year objectives) 
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4.3 LONG- TERM GOALS (3- 5 YEARS) 
 
Blood & Urine Alcohol Programme 
 
1. To maintain ISO 17025 accredited status for blood and urine alcohol analysis 
carried out in the Bureau. (Point 2 of 5 year objectives) 
 
2. To maintain the production and issue of equipment (kits) for the provision of 
blood and urine specimens as required by the Gardaí. (Point 1 of 5 year 
objectives) 
 
 
Breath Alcohol Testing Programme 
 
1. To maintain ISO 17025 accredited status for performance testing of evidential 
breath alcohol testing instruments installed in Garda stations by MBRS scientists. 
(Point 2 of 5 year objectives) 
 
2. To continue to support the Gardaí in the operation of the EBT instruments in 
Garda stations. (Point 1 of 5 year objectives) 
 
3. To maintain ISO 17025 accredited status for performance testing of roadside 
breath alcohol testing devices by Bureau scientists. (Point 2 of 5 year objectives) 
 
4. To continue to support the mandatory alcohol testing legislation and continue to 
replace the current roadside breath alcohol testing devices with those procured in 
2016. (Point 1 of 5 year objectives). 
 
5. To assess technologies used for stationary and mobile evidential breath alcohol 
testing.  
 
 
 
Toxicology Programme 
 
1. To maintain ISO 17025 accredited status for preliminary and confirmatory blood 
and urine drug analysis carried out in the Bureau. (Point 2 of 5 year objectives) 
 
2. To maintain the PDT testing programme. (Point 6 of 5 year objectives) 
 
3. To increase drug testing capability to test all samples received in the Bureau. 
 
4. To expand the drug testing panel in line with emerging trends. 
 
 
 
All Programmes 
 
1. To continue to provide court assistance. (Point 1 of 5 year objectives) 
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2. To develop and train scientific staff to a level which will ensure the laboratories 
competence in forensic toxicology analysis and method development.(Point 4 of 5 
year objectives) 
 
3. To facilitate any further legislative changes that may be planned. (Point 3 of 5 
year objectives) 
 
4. To ensure that all work in the Bureau will be maintained and improved where 
possible to a high standard of quality that is required of a national forensic 
laboratory. (Point 7 of 5 year objectives) 
 
5. To assist with education, enforcement and legislation measures as outlined in the 
2013-2020 National Road Safety Strategy and beyond. (Point 8 of 5 year 
objectives) 
 
 
Corporate Services 
 
1. To continue to maintain the structures and processes in place to conform to the 
Code of Practice for the Governance of State Bodies. (Point 10 of 5 year 
objectives).   
 
2. To ensure that financial management will be maintained in accordance with best 
accounting practice and frameworks. (Point 9 of 5 year objectives). 
 
 
5.0       CHALLENGES FACING THE MEDICAL BUREAU OF ROAD SAFETY 
 
 The provision of sufficient resources both in budget and staffing for the Bureau to 
meet the legal requirements of carrying out its functions. 
 Constant legal challenges to the existing work carried out by the Bureau. 
 Method development and validation for the different classes of drugs to be 
detected.  
 The need for monitoring trends of general alcohol and drug use in order to 
determine which drugs to analyse. 
 Developments in roadside and garda station based and laboratory drug testing. 
 Maintenance and expansion of accreditation to ISO 17025 for all analytical 
testing. 
 Building and maintaining a well trained and competent scientific staff taking 
account of staff turnover and leave requirements  
 Keeping abreast of developments in technologies used for preliminary breath 
alcohol and preliminary drug testing as well as evidential breath testing 
technologies.  
 Maintaining the building, laboratory and IT facility to a level adequate to facilitate 
the forensic testing be maintained at such a high standard. 
 
 
5.1 OPERATING  ENVIRONMENT 
 
The Bureau currently operates under the Road Traffic Acts 1968 to 2016 and the National 
Road Safety Strategy 2013 to 2020. Under this strategy the Bureau will also operate 
under additional road traffic legislation as required.  
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The Bureau also has legal obligations under the Bureau Establishment Order 1968 to the 
Minister of Transport, Tourism and Sport.  It also conforms to the Code of Practice for 
the Governance of State Bodies. 
 
 Provide the Minister with an Annual Report 
 Provide the Minister with a copy of the annual accounts and the auditor’s 
certificate 
 Provide the Minister with information from time to time which may be required 
regarding the functions of the Bureau.  
 
The Bureau is subject to FOI since 2005. Clarification of the records subject to FOI was 
made under RTA 2010. 
 
GDPR 
The Bureau will comply with its obligations under the General Data Protection regulation. 
 
 
5.2  RISK MANAGEMENT PROCESS 
 
Risk management is included as an integral component of the Medical Bureau of Road 
Safety’s planning process in relation to the operational, financial and reputational risks 
that may affect the body.   The executive management team have devised a business 
continuity strategy and set in place a business continuity management process.   
 
5.3  CORPORATE RISK ANALYSIS 
 
On an annual basis, the Board evaluates its approach to risk management and the 
process that the Bureau has in place to mitigate any identified/potential risks. 
 
 
5.4  RISK CONTROLS 
 
Key aspects of the Bureau’s risk management system include: 
 
 Identifying the nature, extent and possible implication of risks facing the Bureau 
 Assessing the likelihood of identified risks occurring 
 Assessing the ability to manage and mitigate risks that do occur 
 
A risk management policy and register is in operation and will continue to be annually 
reviewed. 
 
 
6.0  STRATEGY & IMPLEMENTATION SUMMARY 
 
The scientific programmes within the Bureau have strategies and implementation plans. 
All however can be subdivided in to the following categories: analysis (testing), Quality 
assurance, equipment requirements, court attendances, maintenance and increase of 
forensic toxicology (including alcohol) expertise of the Bureau. All programmes will be 
working towards achieving the goals set out both in the short term and in the long term. 
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6.1 IMPLEMENTATION OF OBJECTIVES 
 
Blood & Urine Alcohol Programme 
 
Blood & Urine Alcohol Analysis 
 
The Bureau will continue to analyse blood and urine specimens for alcohol concentration 
using Gas Chromatography (GC) Headspace analysis. Each specimen is analysed twice by 
two different analysts using two different GC instruments with different chromatographic 
columns. This is international best practice.  
 
The specimen numbers received in the Bureau have been fluctuating over the last few 
years with the current expectation that the numbers will be maintained between 
approximately 3,000 to 4,000 annually during the period of this strategy.   (See important 
assumptions, section 7.1) 
 
Quality Assurance 
 
The Bureau will continue to operate a quality assurance programme in this area in order 
to comply with the requirements of the ISO 17025 standard. (Point 2 of 5 year 
objectives) 
 
Equipment 
 
The need for constant use of instruments also requires the constant review of the 
suitability of the equipment and replacement equipment will be required during the 
lifetime of this strategy. (Point 1 of 5 year objectives) 
 
 
Equipment for the Provision of Specimens 
 
The specimen collection kits for the provision of specimens forwarded to the Bureau are 
prepared and provided to the AGS by the Bureau. (Point 3 of 5 year objectives) 
 
It is envisaged that the Bureau will continue to maintain its kit output annually in line 
with demand.  (See Important Assumptions Section 7.1) (Point 1 of 5 year objectives)  
 
The contents of the kits are constantly kept under review and sourcing of items particular 
to alcohol testing is a constant challenge. Expiry dates were added to kits in 2017 and 
regular recall of issued kits will be carried out over the lifetime of this strategy.  
 
 
Breath Alcohol Testing Programme 
 
Evidential Breath Testing (EBT) 
 
Quality Assurance  
 
The Bureau obtained accreditation under ISO 17025 in 2003 for testing the EBT 
instruments in stations and obtained extension to scope for the replacement instruments 
in 2011. It will continue to maintain this level of quality assurance in its testing 
programme for the lifetime of this strategy. (Point 2 of 5 year objectives) 
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Instruments 
 
There are currently 86 instruments installed in Garda stations nationwide. The Gardai 
select the stations which can change from time to time and the Bureau will work closely 
with Roads Policing (RPMEM) and DTTAS in order to review and maintain the supply to 
the selected stations and supply of any further additional instruments which may be 
required for the lifetime of this strategy. (Point 1 of the 5 year objectives) 
 
 
Schedule of Visits and Level of Testing 
 
Under the RTA the MBRS is responsible for the forensic integrity of the instruments and 
will continue to maintain the instruments in good working order.   The calibration of the 
instruments is now carried out annually at the premises of the manufacturer’s agent in 
Ireland. Post calibration instruments are installed and then tested by a Bureau scientist in 
situ, the instrument is also tested six months post installation.  
 
The Bureau is statistically reviewing (2018) the need for twice yearly visits to Garda 
Stations for the purposes of testing the evidential breath testing instruments. (Point 1 of 
5 year objectives) 
 
Non-scheduled visits will be carried out in response to fault calls made by the Gardaí on 
an as soon as practicable basis.  (Point 1 of 5 year objectives) 
 
Training of Garda operators and supervisors 
 
The Bureau will continue to provide Garda operator and supervisor courses in conjunction 
with the Garda Training College as agreed throughout the lifetime of this strategy. (Point 
1 of 5 year objectives) 
 
Preliminary Alcohol Breath Testing (Roadside Testing) 
 
Equipment 
 
In excess of 1,000 roadside breath testing devices have been issued to the Gardaí.  The 
Bureau was informed in 2013 that production of the devices ended on the 31st December 
2013. Spare parts will be available until 2022.  
 
In 2015 the Bureau reviewed the roadside breath testing devices and commenced the 
procurement process for purchasing alternative devices in 2016 and following years. The 
procurement process was halted and recommenced towards the end of 2016.  The 
procurement process was completed in January 2018 with the awarding of the tender to 
Dräger for provision of the Preliminary Breath Testing Deice the 7510. The new device  
has increased functionality. The provision of these new devices is expected to be 
completed by early 2019. personnel.(Point 1 of 5 year objectives) 
 
 
Provision of Mouthpieces to Gardaí  
 
Current annual usage is estimated at 300,000 mouthpieces, which are issued as 
requested by An Garda Síochána.  This number will be reviewed in order to maintain the 
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mandatory alcohol testing legislation and the additional provision with regard to breath 
testing introduced in the RTA 2011. (Point 8 of 5 year objectives) 
 
Routine Testing 
 
Each device is scheduled for recalibration on a six-monthly basis. The Bureau will 
continue to test and calibrate the Draeger devices in the laboratory. The Bureau will 
implement a hot swap system of recalibration and testing on a six monthly basis, thus 
improving efficiency for Garda personnel. The Bureau also carries out in house repair of 
these devices when required and expect to continue to carry out these repairs on 
replacement devices. (Point 1 of 5 year objectives). 
 
Quality Assurance  
 
The Bureau will seek accreditation under ISO 17025 in 2018 for new roadside breath 
alcohol devices. It will continue to maintain a high level of quality assurance in its testing 
programme for the lifetime of this strategy. (Point 2 of 5 year objectives) 
 
 
Toxicology Programme 
 
Blood & Urine Drug Analyses 
 
Drug Screening 
 
The Bureau will continue the analysis of all blood and urine specimens found under the 
80 mg/100ml blood limit (and equivalent urine limit) for alcohol, for the presence of drug 
or drugs.  Specimens are also tested for drugs where an information form has been 
forwarded indicating that the Preliminary Drug Testing Device has been used and 
indicated a positive result. 
  
Gardaí can continue to request drug analyses on specimens with alcohol levels above the 
80mg/100ml blood alcohol legal limit and also for specimens where an EBT statement for 
breath alcohol content has already been issued.  (Point 1 of 5 year objectives) 
 
The number of specimens analysed for the presence of a drug or drugs has increased 
significantly since the introduction of preliminary Drug Testing in oral fluid.  In Autumn 
2018 the Bureau will be moving from using immunoassay to LCMSMS technology to 
screen for drugs.   
 
The Bureau will continue to review its testing capacity and aim to expand drug testing to 
all specimens regardless of alcohol level 
 
 
Equipment  
 
The Bureau will phase out the maintenance of the immunoassay equipment over 2018 as 
the LCMSMS capacity increases.   New instrumentation will be purchased over the 
lifetime of this strategy to address the increased amount of testing, the continued 
requirement for development of expanded testing and instrument redundancy. The 
Bureau will continue to keep up to date with drug driving prevalence and detection 
methodologies. (Point 1 of 5 year objectives) 
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Quality Assurance  
 
The Bureau will seek accreditation to ISO 17025 for the preliminary analysis carried out 
by chromatographic means as these tests are incorporated into routine analysis and will 
continue to operate a quality assurance programme in this area to retain its ISO 17025 
accredited status. (Point 2 of 5 year objectives) 
 
 
Confirmatory analysis  
 
Cannabinoids and benzodiazepines continue to be the most prevalent drugs detected in 
specimens analysed.  The Bureau will continue to carry out all confirmatory testing for 
the presence of cannabinoids and benzodiazepine in blood and urine specimens. In 2017 
the Bureau commenced confirmation of all other blood specimens which were positive in 
screening in the Bureau’s UCD facility. In 2018 this was extended to all urine specimens 
being confirmed in the Bureau’s UCD laboratory. All confirmatory testing will be carried 
out in the UCD facility hence forth. 
 
The Bureau will carry out confirmatory drug testing on specimens for as many drugs as 
the volume of specimen allowed and where specimens had screened positive for multiple 
drugs. This procedure will continue and methods will be developed to reduce test volume 
requirements to enable further testing.  
 
The Bureau will continue to quantify and report drug concentrations for drugs specified in 
the RTA 2016.  
 
(See Important Assumption, Section 7.1) (Point 5 of 5 year objectives) 
 
Equipment  
 
Additional sample preparation instrumentation will be required during the life time of this 
strategy.  Also older instruments will be kept under review and will need to be replaced 
towards the end of this five year strategy period. (Point 7 of 5 year objectives). 
 
New instrumentation will be purchased over the lifetime of this strategy to address the 
increased amount of testing, the continued requirement for development of expanded 
testing and instrument redundancy 
 
Quality Assurance  
 
The Bureau has obtained accreditation to ISO 17025 for the confirmatory analysis  
carried out in the Bureau in 2012 and has obtained accreditation for flexible scope for 
additional toxicology  analysis in 2013. The Bureau will continue to operate a quality 
assurance programme in this area to retain its ISO 17025 accredited status and to 
expand accreditation to all tests as they are incorporated into routine analysis. (Point 2 of 
5 year objectives) 
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Preliminary Drug Testing(PDT) 
 
The use of PDT devices was commenced in April 2017.  86 devices are located in 
intoxicant testing garda stations alongside the EBT instruments and 50 devices were 
made available to AGS for mobile use. (See Important Assumptions, section 7.1) 
 
The Bureau will continue to maintain and test the devices on a six month basis. The 
Bureau will continue to review the procedures involved in return and testing of devices.  
 
Bureau staff will continue to train garda trainers on use of the devices where required in 
agreement with the RPMEM.  
 
A second procurement process for a PDT solution will be commenced within the life time 
of this strategy as the current framework agreement will expire within this time frame.   
 
The Bureau will continue to participate in any surveys or research in this area. (Point 6 of 
5 year objectives) 
 
The Bureau will continue to test drugs in oral fluid in order to enable the laboratory to 
quality check the consumable part (STKs) of the PDT device on a regular basis as new 
batches of STKs are purchased.  
 
 
 
Research 
 
Drugs and driving (DUID) continues to be an area of concern to the Government 
especially with regard to enforcement.  The type of research area that the Bureau will be 
involved in will be decided by the Director, in consultation with the Department of 
Transport, Tourism and Sport (DTTAS), as part of the Government’s Road Safety 
Strategy.  (Point 8 of 5 year objectives) 
 
The Toxicology programme continues to monitor specimens which have returned 
negative drug and alcohol result and look for ‘unknowns’ using a High Resolution Mass 
Spectrometry instrument. 
 
 
 
All Programmes 
 
Court Attendances 
 
The requests by Prosecution and Defence solicitors for MBRS scientists to attend courts 
nationwide and present evidence with regard to Bureau analysis for alcohol and drugs 
and for evidential breath alcohol testing is part of the service of the Bureau. It is 
envisaged that legal challenges will continue to demand the time of both administrative 
and analytical staff both in and out of court.  (Point 1 of 5 year objectives) 
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Forensic Toxicology (Including Alcohol) Knowledge – Base within the Bureau 
 
The quantity and quality of the work of the Bureau will be maintained by a high level of 
staff training. The analysis is extremely labour/instrumentation intensive with a high skill 
requirement.  All analytical staff have a third level qualifications and most have post 
graduate qualifications.  
 
Analysts are required to follow well planned training programmes to completion before 
being permitted to sign a statutory certificate on behalf of the Bureau.  
 
Forensic alcohol and toxicological knowledge is acquired by several routes, by 
qualification, reading relevant scientific journals, attendance at courses, conferences and 
meetings, building up relationships with similar laboratories within the country and 
overseas.  All analysts are expected to conduct self directed learning. The Bureau will 
continue to invest in training to maintain the highest forensic standards. 
 (Point 4 of 5 year objectives) 
 
General Staff Development 
 
All staff are reviewed annually and are encouraged to attend suitable courses, which are 
relevant to the work of the Bureau and for their own personal development. (Point 7 of 5 
year objectives) 
 
IT Services 
 
The Bureau is provided with IT services from UCD but it also has an independent Local  
Area Network system (LAN) which was installed in 2009 and continues to expand 
annually.  (Points 7 & 8 of 5 year objectives) The LAN is providing much needed 
assistance with managing the Bureau’s many functions.  Data protection, security and IT 
upgrading are important features of the Bureau IT services. In 2017 a back up system 
was installed to enable systems and data to be backed up off site and facilitate quick 
restore if required. This system requires maintenance and monitoring on an ongoing 
basis. 
 
Laboratory Information Management System (LIMS) 
 
The Bureau purchased a LIMS in 2010 and the first phase of the implementation strategy 
was completed by mid 2011.   The strategy commenced with the blood and urine alcohol 
programme has expanded to include the toxicology programme and PBT programme. As 
new test methods come on stream there is a requirement for instrument integration and 
a requirement for IT consultation to be bought in for particular projects, this will augment 
the IT skills Bureau staff are developing. 
 
The Bureau will continue to review the use of LIMS in line with developments in the 
different programmes and software upgrades over the lifetime of the strategy. (points 1, 
7 & 8 of 5 year objectives). 
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Quality Management System 
 
The Bureau operates an electronic Quality Management System.  The Bureau uses the 
system to maintain and record, documentation, training, equipment, non-conformances, 
complaints, improvements and staff continuous professional development. (Points 1, 2 & 
7 of 5year objectives) The Bureau will continue to access upgrades to this system 
throughout the lifetime e of this strategy. 
 
Corporate Services 
 
To improve the efficiency of the financial management it is planned to update accounting 
software.  (Point 9 of 5 year objectives) 
 
 
6.2 PERFORMANCE INDICATORS 
 
The main performance indicator for the quality of the work of the Bureau is in the 
maintenance of its ISO accreditation status for the analytical activities accredited. 
The Bureau participates in external proficiency testing for each of its programmes. There 
are also specific performance indicators for the specific programmes. 
 
In the Blood & Urine Alcohol Programme the specific indicators are  
 The specimens will continue to be analysed as soon as practicable within the 
meaning of the legislation.  
 A sufficient number of the analytical staff will be trained to competent level to 
carry out the analysis and be capable of providing expert witness testimony on 
behalf of the Bureau.  
 The levels of specimen collection kits will continue to be provided to the Gardaí to 
meet their requirements. 
 Successful participation in external Proficiency Testing (PT) schemes.  
 
In the Breath Alcohol Testing Programme the specific indicators are 
 A sufficient number of the analytical staff will be trained to competent level to 
carry out the testing of instruments and devices and be capable of providing 
expert witness testimony on behalf of the Bureau.  
 As many as possible of the instruments in stations and the roadside breath 
alcohol testing devices will be maintained and available for use by Garda 
operators at any given time.  
 Successful participation in external PT scheme and internal PT scheme.  
 The Bureau to provide the number of new instruments in stations as required by 
Gardaí in an agreed timeframe.  
 The Bureau to provide the Gardaí with courses for operators/supervisors in an 
agreed time frame.  
 The Bureau will provide and maintain sufficient roadside breath testing devices as 
required by the Gardai. 
 
In the Toxicology Programme the specific indicators are 
 The specimens will continue to be analysed as soon as practicable within the 
meaning of the legislation. 
 A sufficient number of the analytical staff will be trained to competent level to 
carry out the analysis and be capable of providing expert witness testimony on 
behalf of the Bureau.  
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 Confirmatory analysis in use for the drug classes to be maintained 
 Additional drug classes to be set up and validated at Bureau premises at UCD.  
 Monitoring of changes in drug trends to assist with the appropriate choices of 
drug classes for testing in the Bureau.  
 Successful participation in several external PT schemes. 
 Add tests to list of additional accredited tests under flexible scope. 
 Add additional tests to LIMS system. 
 Provide the Gardaí with preliminary drug testing devices in line with legislative 
requirements. 
 
In the Corporate Services the specific indicators are 
 The monthly accounting statements will continue to be reconciled as soon as 
practicable. 
 Preparation of the annual financial statements for audit by the Comptroller and 
Auditor General in a timely manner. 
 Preparation of essential reports as required under the Code of Practice for the 
Governance of State Bodies. 
 
 
6.3        ACHIEVEMENTS AGAINST PERFORMANCE INDICATORS 
 
The main achievement of the Bureau is the continued acceptance by the courts of the 
forensic results issued by the Bureau.   
 
Achievements by the Bureau will be measured by the quality and quantity of the service 
provided in alcohol and drug analyses and the supply of equipment to the Gardai for the 
provision of the specimens.  
 
It will also measure achievements against the supply and testing of roadside drug testing 
devices to the highest forensic standards. 
 
It will also measure achievements against the supply and testing of the EBT instruments 
and the roadside testing devices to the highest forensic standards.  
 
The continuing maintenance of accreditation to ISO 17025 standard for the activities 
already accredited and to achieve accreditation for new confirmatory drug analysis as 
they are developed.  
 
Continued success is maintained in proficiency testing schemes for all programmes. 
 
Effective financial management systems as measured by internal audits and audits of the 
Comptroller and Auditor General. 
 
 
7.0 5 YEAR FINANCIAL PLAN 
 
The Medical Bureau of Road Safety receives its funding from an annual grant out of the 
vote for the Department of Transport Tourism and Sport.   
 
The budget requirements are based on the performance indicators set out within the 
strategic plans.    
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7.1 IMPORTANT ASSUMPTIONS 
 
The Bureau in devising its 5 year financial plan has based it on the following assumptions 
of:  
 Expected workloads within the different programmes are as outlined in table 1 
below. 
 Staffing levels will increase by 5 above the current Employment Control 
Framework level.  
 Sufficient Instrumentation is provided for the individual programmes including IT. 
 Allowance has been made within the projected capital estimate for replacement of 
essential laboratory equipment but does not allow for any significant breakdown 
within any of the programmes. 
 The Bureau has estimated the expenditure within the building utilities based on 
the costings for the previous three years. 
 The Bureau has included projected development costs for the toxicology 
programme over the lifetime of the strategy. 
 
 
7.2 Key Financial Indicators 
 
The main key financial indicators for the effectiveness of financial management for the 
Bureau are: 
 
Funding - The Bureau to continue to obtain sufficient funding to operate all of its 
functions. 
 
Financial Cost Effectiveness - The Bureau is committed to continuing to maintain 
financial cost effectiveness by annually reviewing its suppliers and monitoring 
expenditure within all areas.    The Bureau under a Licence Agreement with University 
College Dublin has the availability of being able to utilise a number of shared services i.e. 
IT, utilities, HR expertise, Bursars Office and many others.  On an annual basis the 
Bureau re-negotiates service level agreements in order to ensure best practice. 
 
Continuation of use of Preferred Suppliers Listings – The Bureau to continue to 
use agreed preferred suppliers on the UCD lists when possible. 
 
 
7.3 Projected Financing Requirements 
 
Appendix 1 shows the financing requirements during the period 2019 – 2023. 
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APPENDIX 1 
 
PROJECTED INCOME AND EXPENDITURE ACCOUNT 
 
2019 – 2023 
 
 
 
 
INCOME 
 
 
2019 
 
2020 
 
2021 
 
2022 
 
2023 
 € € € € € 
 
Oireachtas Grant 
 
6,154,000 
 
5,984,000 
 
6,034,000 
 
6,084,000 
 
6,134,000 
 
 
 
 
EXPENDITURE 
 
 
2019 
 
2020 
 
2021 
 
2022 
 
2023 
PAY € € € € € 
 
Salaries and Wages 
 
3,216,000 
 
3,266,000 
 
 
3,316,000 
 
3,366,000 
 
3,416,000 
NON PAY      
Alcohol Programme 703,000 703,000 703,000 703,000 703,000 
Drug Analysis 
Programme 
 
590,000 
 
590,000 
 
590,000 
 
590,000 
 
590,000 
Roadside Chemical Drug 
Testing 
 
200,000 
 
200,000 
 
200,000 
 
200,000 
 
200,000 
Evidential Breath 
Testing Programme 
 
345,000 
 
345,000 
 
345,000 
 
345,000 
 
345,000 
Breath Screening Devices 
Programme 
 
180,000 
 
180,000 
 
180,000 
 
180,000 
 
180,000 
IT Programme 110,000 100,000 100,000 100,000 100,000 
 
CAPITAL 
 
 
    
 
Capital 
 
810,000 
 
600,000 
 
600,000 
 
600,000 
 
600,000 
 
Surplus/(Deficit) for Year 
 
Nil 
 
Nil 
 
NIL 
 
NIL 
 
Nil 
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Table 1 
Performance Assumptions 
 
     
Alcohol Programme  2019 2020 2021 2022 2023 
        
Number of specimens  3,500 3,500 3,500 3,500 3,500 
Number of kits prepared 5,000 5,000 5,000 5,000 5,000 
Number of kits issued 5,000 5,000 5,000 5,000 5,000 
        
Toxicology Programme      
        
Number of specimens       
Preliminary analyses 2,000 2,000 2,000 2,000 2,000 
Confirmatory analyses 1,500 1,500 1,500 1,500 1,500 
        
PDT       
No of Devices supported  150* 150* 150* 150* 150* 
Training Courses(Train the 
Trainer) 
 2 2 2 2 2 
 
Breath Testing Programme 
      
      
EBT      
No of instruments supported 86 86 86 86 86 
Testing in stations/laboratory 190 190 200 200 200 
No of training courses EBT      
Operator  20 20 20 20 20 20 
Supervisor  10 10 10 10 10 10 
        
PBT      
Training Courses(Train the Trainer) 5     
No of Devices supported PBT 1,400 1,400 1,400 1,400 1,400 
        
 
 
 
*Requirement to be reviewed quarterly by the Bureau and An Garda Síochána.  
 
